NO20082145L - Prolinamidderivater som natriumkanalmodulatorer - Google Patents
Prolinamidderivater som natriumkanalmodulatorerInfo
- Publication number
- NO20082145L NO20082145L NO20082145A NO20082145A NO20082145L NO 20082145 L NO20082145 L NO 20082145L NO 20082145 A NO20082145 A NO 20082145A NO 20082145 A NO20082145 A NO 20082145A NO 20082145 L NO20082145 L NO 20082145L
- Authority
- NO
- Norway
- Prior art keywords
- sodium channel
- channel modulators
- prolinamide derivatives
- prolinamide
- derivatives
- Prior art date
Links
- 108010052164 Sodium Channels Proteins 0.000 title abstract 2
- 102000018674 Sodium Channels Human genes 0.000 title abstract 2
- VLJNHYLEOZPXFW-BYPYZUCNSA-N L-prolinamide Chemical class NC(=O)[C@@H]1CCCN1 VLJNHYLEOZPXFW-BYPYZUCNSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000001419 dependent effect Effects 0.000 abstract 1
- 208000037765 diseases and disorders Diseases 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Addiction (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Hydrogenated Pyridines (AREA)
- Pyrrole Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0520581A GB0520581D0 (en) | 2005-10-10 | 2005-10-10 | Novel compounds |
| GB0523045A GB0523045D0 (en) | 2005-11-11 | 2005-11-11 | Novel compounds |
| GB0603900A GB0603900D0 (en) | 2006-02-27 | 2006-02-27 | Novel compounds |
| GB0618336A GB0618336D0 (en) | 2006-09-18 | 2006-09-18 | Novel compounds |
| PCT/EP2006/009731 WO2007042239A1 (en) | 2005-10-10 | 2006-10-06 | Prolinamide derivatives as sodium channel modulators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20082145L true NO20082145L (no) | 2008-05-07 |
Family
ID=37546777
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20082145A NO20082145L (no) | 2005-10-10 | 2008-05-07 | Prolinamidderivater som natriumkanalmodulatorer |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US7655693B2 (de) |
| EP (1) | EP1934177B8 (de) |
| JP (1) | JP5139305B2 (de) |
| KR (1) | KR101282464B1 (de) |
| AR (1) | AR056575A1 (de) |
| AT (1) | ATE556049T1 (de) |
| AU (1) | AU2006301470B2 (de) |
| BR (1) | BRPI0616944B8 (de) |
| CA (1) | CA2625642C (de) |
| CR (1) | CR9898A (de) |
| EA (1) | EA015736B1 (de) |
| ES (1) | ES2387405T3 (de) |
| IL (1) | IL192627A0 (de) |
| MA (1) | MA29817B1 (de) |
| NO (1) | NO20082145L (de) |
| NZ (1) | NZ567051A (de) |
| PE (1) | PE20070592A1 (de) |
| PL (1) | PL1934177T3 (de) |
| TW (1) | TW200730494A (de) |
| WO (1) | WO2007042239A1 (de) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8143306B2 (en) * | 2005-10-10 | 2012-03-27 | Convergence Pharmaceuticals Limited | Methods of treating bipolar disorders |
| EP1943216B1 (de) * | 2005-10-10 | 2010-06-30 | Glaxo Group Limited | Prolinamidderivate als natriumkanalmodulatoren |
| GB0701365D0 (en) * | 2007-01-24 | 2007-03-07 | Glaxo Group Ltd | Novel pharmaceutical compositions |
| GB0706630D0 (en) * | 2007-04-04 | 2007-05-16 | Glaxo Group Ltd | Novel compounds |
| EP2461807A1 (de) | 2009-08-05 | 2012-06-13 | Convergence Pharmaceuticals Limited | Kombinationstherapie zur behandlung von epilepsie und assoziierten erkrankungen |
| US8759542B2 (en) | 2009-09-14 | 2014-06-24 | Convergence Pharmaceuticals Limited | Process for preparing alpha-carboxamide derivatives |
| EP2681200A4 (de) | 2011-03-03 | 2015-05-27 | Zalicus Pharmaceuticals Ltd | Benzimidazolhemmer des natriumkanals |
| GB201122113D0 (en) | 2011-12-22 | 2012-02-01 | Convergence Pharmaceuticals | Novel compounds |
| GB201209015D0 (en) | 2012-05-22 | 2012-07-04 | Convergence Pharmaceuticals | Novel compounds |
| CA2936886A1 (en) | 2014-02-27 | 2015-08-03 | Merck Patent Gmbh | Heterocyclic compounds as nav channel inhibitors and uses thereof |
| GB201417497D0 (en) | 2014-10-03 | 2014-11-19 | Convergence Pharmaceuticals | Novel use |
| GB201417499D0 (en) | 2014-10-03 | 2014-11-19 | Convergence Pharmaceuticals | Novel use |
| GB201417500D0 (en) | 2014-10-03 | 2014-11-19 | Convergence Pharmaceuticals | Novel use |
| EP3237379B1 (de) | 2014-12-23 | 2022-04-06 | Convergence Pharmaceuticals Limited | Verfahren zur herstellung von alpha-carboxamid-pyrrolidinderivaten |
| MX2019005121A (es) * | 2016-11-02 | 2019-10-07 | Biogen Ma Inc | Novedoso regimen de dosificacion. |
| CN110913852A (zh) * | 2017-05-19 | 2020-03-24 | 生物基因麻省公司 | 新结晶形式 |
| MX2020003811A (es) | 2017-10-05 | 2021-01-15 | Biogen Inc | Proceso para preparar derivados de alfa-carboxamida pirrolidina. |
| EP3694510A4 (de) | 2017-10-10 | 2021-06-30 | Biogen Inc. | Verfahren zur herstellung von spiroderivaten |
| CN112367990A (zh) * | 2018-04-16 | 2021-02-12 | 生物基因麻省公司 | 治疗神经病理性疼痛的方法 |
| MX2021012421A (es) * | 2019-04-10 | 2022-02-10 | Biogen Inc | Procesos para preparar derivados de pirrolidina alfa-carboxamida. |
| EA202192762A1 (ru) * | 2019-04-10 | 2022-03-21 | Байоджен Ма Инк. | Способ получения производных альфа-карбоксамид пирролидина |
| EP4096508A4 (de) | 2020-01-30 | 2024-03-27 | Javed, Mohammad | Kombinationsarzneitherapien für zns-erkrankungen |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL94466A (en) | 1989-05-25 | 1995-01-24 | Erba Carlo Spa | Pharmaceutical preparations containing the history of A-amino carboxamide N-phenylalkyl are converted into such new compounds and their preparation |
| US6201016B1 (en) | 1994-06-27 | 2001-03-13 | Cytomed Incorporated | Compounds and methods for the treatment of cardiovascular, inflammatory and immune disorders |
| GB9727523D0 (en) | 1997-12-31 | 1998-02-25 | Pharmacia & Upjohn Spa | Alpha-aminoamide derivatives useful as analgesic agents |
| US6136131A (en) * | 1998-06-02 | 2000-10-24 | Instrument Specialties Company, Inc. | Method of shielding and obtaining access to a component on a printed circuit board |
| IL145508A0 (en) | 1999-03-26 | 2002-06-30 | Euro Celtique Sa | Aryl substituted pyrazole, imidazole, oxazole, thiazole and pyrrole derivatives and pharmaceutical compositions containing the same |
| GB9923748D0 (en) | 1999-10-07 | 1999-12-08 | Glaxo Group Ltd | Chemical compounds |
| GB0115517D0 (en) | 2001-06-25 | 2001-08-15 | Ferring Bv | Novel antidiabetic agents |
| TW200404796A (en) * | 2002-08-19 | 2004-04-01 | Ono Pharmaceutical Co | Nitrogen-containing compound |
| PA8583001A1 (es) * | 2002-09-20 | 2004-04-23 | Hoffmann La Roche | Derivados de 4-pirrolidino-fenil-bencil eter como inhibidores de mao-b |
| MY142651A (en) | 2003-03-18 | 2010-12-15 | Merck Sharp & Dohme | Biaryl substituted triazoles as sodium channel blockers |
| CN1798738A (zh) | 2003-04-03 | 2006-07-05 | 麦克公司 | 作为钠通道阻滞剂的联芳基取代吡唑 |
| AU2004232936B2 (en) * | 2003-04-18 | 2008-10-30 | Merck & Co., Inc. | Biaryl substituted thiazoles, oxazoles and imidazoles as sodium channel blockers |
| WO2005000309A2 (en) * | 2003-06-27 | 2005-01-06 | Ionix Pharmaceuticals Limited | Chemical compounds |
| EP1524265A1 (de) | 2003-10-15 | 2005-04-20 | Newron Pharmaceuticals S.p.A. | Prolinamide-Derivate als Natrium- und/oder Kalziumkanalblocker oder selektive MAO-B Inhibitoren |
| WO2005100334A1 (en) | 2004-04-14 | 2005-10-27 | Pfizer Products Inc. | Dipeptidyl peptidase-iv inhibitors |
| WO2006119451A1 (en) | 2005-05-04 | 2006-11-09 | Vertex Pharmaceuticals Incorporated | Pyrimidines and pyrazines useful as modulators of ion channels |
| EP1877381A1 (de) | 2005-05-04 | 2008-01-16 | Vertex Pharmaceuticals Incorporated | Pyridine zur modulation von ionenkanälen |
| EP1888549A2 (de) | 2005-05-19 | 2008-02-20 | Vertex Pharmaceuticals, Inc. | Als modulatoren von ionenkanälen geeignete biaryle |
| NZ565983A (en) | 2005-09-09 | 2011-04-29 | Smithkline Beecham Corp | Pyridine derivatives and their use in the treatment of psychotic disorders |
| EP1943216B1 (de) | 2005-10-10 | 2010-06-30 | Glaxo Group Limited | Prolinamidderivate als natriumkanalmodulatoren |
| TW200728258A (en) | 2005-10-10 | 2007-08-01 | Glaxo Group Ltd | Novel compounds |
| BRPI0807972A2 (pt) | 2007-01-24 | 2014-06-10 | Glaxo Group Ltd | Composições farmacêuticas compreendendo 3,5-diamino-6-(2,3-diclofenil)-l,2,4-triazina ou r(-)-2,4-diamino-5-(2,3-diclorofenil)-6-fluorometilpirim idina e uma nk1 |
| GB0701365D0 (en) | 2007-01-24 | 2007-03-07 | Glaxo Group Ltd | Novel pharmaceutical compositions |
| GB0701366D0 (en) | 2007-01-24 | 2007-03-07 | Glaxo Group Ltd | Novel pharmaceutical compositions |
| GB0706630D0 (en) | 2007-04-04 | 2007-05-16 | Glaxo Group Ltd | Novel compounds |
-
2006
- 2006-10-05 TW TW095136986A patent/TW200730494A/zh unknown
- 2006-10-06 CA CA2625642A patent/CA2625642C/en active Active
- 2006-10-06 NZ NZ567051A patent/NZ567051A/en unknown
- 2006-10-06 EA EA200801054A patent/EA015736B1/ru not_active IP Right Cessation
- 2006-10-06 ES ES06806110T patent/ES2387405T3/es active Active
- 2006-10-06 WO PCT/EP2006/009731 patent/WO2007042239A1/en active Application Filing
- 2006-10-06 EP EP06806110A patent/EP1934177B8/de active Active
- 2006-10-06 US US11/570,560 patent/US7655693B2/en active Active
- 2006-10-06 PE PE2006001225A patent/PE20070592A1/es not_active Application Discontinuation
- 2006-10-06 JP JP2008534910A patent/JP5139305B2/ja not_active Expired - Fee Related
- 2006-10-06 PL PL06806110T patent/PL1934177T3/pl unknown
- 2006-10-06 AT AT06806110T patent/ATE556049T1/de active
- 2006-10-06 KR KR1020087011271A patent/KR101282464B1/ko active IP Right Grant
- 2006-10-06 BR BRPI0616944A patent/BRPI0616944B8/pt not_active IP Right Cessation
- 2006-10-06 AU AU2006301470A patent/AU2006301470B2/en not_active Ceased
- 2006-10-09 AR ARP060104441A patent/AR056575A1/es not_active Application Discontinuation
-
2008
- 2008-03-31 MA MA30797A patent/MA29817B1/fr unknown
- 2008-04-18 CR CR9898A patent/CR9898A/es not_active Application Discontinuation
- 2008-05-07 NO NO20082145A patent/NO20082145L/no not_active Application Discontinuation
- 2008-07-03 IL IL192627A patent/IL192627A0/en active IP Right Grant
-
2009
- 2009-12-17 US US12/641,111 patent/US8153681B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| US8153681B2 (en) | 2012-04-10 |
| KR20080059296A (ko) | 2008-06-26 |
| NZ567051A (en) | 2011-03-31 |
| ES2387405T3 (es) | 2012-09-21 |
| US20080280969A1 (en) | 2008-11-13 |
| US20100105754A1 (en) | 2010-04-29 |
| PE20070592A1 (es) | 2007-06-23 |
| EA200801054A1 (ru) | 2008-08-29 |
| IL192627A0 (en) | 2011-08-01 |
| KR101282464B1 (ko) | 2013-07-04 |
| EP1934177B1 (de) | 2012-05-02 |
| JP2009511519A (ja) | 2009-03-19 |
| US7655693B2 (en) | 2010-02-02 |
| BRPI0616944B8 (pt) | 2021-05-25 |
| MA29817B1 (fr) | 2008-09-01 |
| BRPI0616944B1 (pt) | 2020-04-14 |
| CA2625642C (en) | 2013-12-24 |
| AU2006301470A1 (en) | 2007-04-19 |
| EP1934177B8 (de) | 2012-09-05 |
| JP5139305B2 (ja) | 2013-02-06 |
| WO2007042239A1 (en) | 2007-04-19 |
| TW200730494A (en) | 2007-08-16 |
| AU2006301470B2 (en) | 2012-06-14 |
| EP1934177A1 (de) | 2008-06-25 |
| BRPI0616944A2 (pt) | 2011-07-05 |
| CA2625642A1 (en) | 2007-04-19 |
| PL1934177T3 (pl) | 2013-03-29 |
| CR9898A (es) | 2008-07-29 |
| ATE556049T1 (de) | 2012-05-15 |
| AR056575A1 (es) | 2007-10-10 |
| EA015736B1 (ru) | 2011-10-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20082145L (no) | Prolinamidderivater som natriumkanalmodulatorer | |
| ATE472529T1 (de) | Prolinamidderivate als natriumkanalmodulatoren | |
| NO20070855L (no) | Arylidener for behandling av estrogenrelaterte reseptor-alfamedierte sykdommer. | |
| MX2007007845A (es) | Sulfonilpirrolidinas, metodo para producir las mismas y su uso como medicamento. | |
| TW200728258A (en) | Novel compounds | |
| NO20081788L (no) | Cyklopropylaminer som modulatorer av histamin-H3-reseptoren | |
| MX2009002002A (es) | Derivados de 4-(n-azacicloalquil) anilidas como moduladores de canal de potasio. | |
| EA201001848A1 (ru) | Производные пиразина в качестве блокаторов эпителиальных натриевых каналов | |
| NO20056130L (no) | Nye substituerte 3-svovelindoler | |
| NO20063576L (no) | 1,3-dioksanederivativer og analoge forbindelser for behandling av fedme og diabetes | |
| NO20080675L (no) | P38-Map kinaseinhibitorer og metoder for deres anvendelse | |
| NO20061092L (no) | Heteroarvlaminosulfonvlfenvl-derivater for anvendelse som natrium- eller kalslumkanalblokkere i behandlingen av smerte | |
| EA201000886A1 (ru) | Органические соединения | |
| NO20081315L (no) | Benzokinazolinderivater og deres anvendelse ved behandling av benlidelser | |
| NO20076306L (no) | Bicykliske derivater som modulatorer av ionekanaler | |
| WO2007067711A3 (en) | Certain chemical entities, compositions, and methods for modulating trpv1 | |
| NO20081846L (no) | Bifenylderivater og deres anvendelse ved behandling av hepatitt C | |
| NO20073926L (no) | Pyrazolforbindelser som modulerer aktivitet av CDK-, GSK- og aurorakinaser | |
| NO20085029L (no) | Substituerte pyridylamidforbindelser som modulatorer av histamin H3 reseptoren | |
| EA200600203A1 (ru) | Производные 2-(хиноксалин-5-илсульфониламино)бензамида в качестве модуляторов сск2 | |
| EA200801011A1 (ru) | Производные пиразина как модуляторы натриевых каналов для лечения боли | |
| NO20076254L (no) | Nye 2-azetidinonderivater som kolesterolabsorpsjonsinhibitorer for behandling av hyperlipidemiske tilstander | |
| NO20076137L (no) | Nye 2-azetidinonderivater og deres anvendelse som kolestrolabsorpsjonsinhibitorer for behandling av hyperlipidemi | |
| NO20054787D0 (no) | Indenderivater som farmasotiske midler | |
| TW200740429A (en) | Methods and dosage forms for reducing side effects of carbamate compounds |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |